FRES
Fresh2FRES
FRES
About: Fresh2 Group Ltd is a biotechnology company. It focuses on early cancer screening and detection. The company markets and sells a multi-cancer screening and detection test that uses its innovative patented CDA technology and its proprietary CDA device. In addition to early cancer screening and detection, its CDA technology has demonstrated the potential to assist physicians in cancer diagnosis, prognosis, and recurrence.
Employees: 75
0
Funds holding %
of 6,740 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
491% more capital invested
Capital invested by funds: $3.67K [Q1] → $21.7K (+$18K) [Q2]
200% more funds holding
Funds holding: 1 [Q1] → 3 (+2) [Q2]
0.01% more ownership
Funds ownership: 0% [Q1] → 0.01% (+0.01%) [Q2]
Research analyst outlook
We haven’t received any recent analyst ratings for FRES.
Financial journalist opinion
Charts implemented using Lightweight Charts™